Aminologics아미노로직스

Aminologics has returned to profit on a trailing basis, but its share price is down over the past three months and sits far below its 52-week high.

Aminologics, a Korean maker of pharmaceutical raw ingredients and amino acid derivatives, reported trailing twelve-month revenue of ₩26.2B and net income of ₩3.2B to H1 2026. Its 2025 results were a clear recovery from the loss-making 2024 year, though the share price has fallen 6.6% over one month and 5.3% over three months. The filing record shows mainly shareholding reports and convertible bond conversion and call-option notices, and no news headlines were available in the data.

What stands out

• Trailing operating margin is 20.9% and net margin 12.1%, versus a 16.3% operating margin for 2025 and a loss in 2024.
• Revenue has been volatile: it fell 19.6% in 2024 and rose 31.1% in 2025, and 2022 net income was a large loss of ₩7.3B.
• The balance sheet carries ₩16.2B of borrowings against ₩23.1B of cash, with liabilities at 53.5% of equity.
• The share price of ₩997 is near the DCF base value of ₩549 only in the sense that it sits well above it; the model's bear-to-bull range is ₩388 to ₩819, so the price is above the model's bull case.
• Foreign ownership is unchanged at 2.4% over 60 days, and 20-day flows show foreign buying against domestic retail selling.

What to watch

• Convertible bond conversion and call-option filings from September 2026, which could affect the share count.
• Whether trailing profitability holds in the next full-year and quarterly results, given the swings in past years.
• Recent 5%+ holding and insider shareholding reports, which the data does not explain in detail.